Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts
Brigimadlin is highly effective in <i>MDM2</i>-amplified GBM when adequate drug levels are achieved in tumor tissue. <i>MDM2</i> amplification impacts both treatment efficacy and intratumoral drug accumulation.
Authors
- Patrizia Sini (ORCID: https://orcid.org/0009-0002-0326-6093)
- Katrina K. Bakken (ORCID: https://orcid.org/0009-0009-8900-0077)
- Lauren L. Ott (ORCID: https://orcid.org/0009-0009-9109-317X)
- Jann Nagina Sarkaria (ORCID: https://orcid.org/0000-0001-7489-4885)
- Rachael A. Vaubel (ORCID: https://orcid.org/0000-0001-8842-5975)
- William F. Elmquist (ORCID: https://orcid.org/0000-0002-7478-3429)
- Danielle M. Burgenske (ORCID: https://orcid.org/0000-0003-0014-5579)
- Jeanette E. Eckel‐Passow (ORCID: https://orcid.org/0000-0002-6113-1114)
- Surabhi Talele (ORCID: https://orcid.org/0009-0008-1604-1233)
- Brett L. Carlson (ORCID: https://orcid.org/0000-0003-2460-3079)
- Ju-Hee Oh
- Paul A. Decker (ORCID: https://orcid.org/0000-0002-3756-4227)
- Katie L. Waller (ORCID: https://orcid.org/0009-0004-2275-4062)
- Matt Kosel
- Nishika Karbhari (ORCID: https://orcid.org/0000-0002-3360-6733)
- Zeng Hu (ORCID: https://orcid.org/0009-0003-1781-5812)
- Sonia Jain (ORCID: https://orcid.org/0000-0002-3728-6642)
- Ann C. Mladek (ORCID: https://orcid.org/0000-0002-0508-6531)
- Tugce I. Pasa (ORCID: https://orcid.org/0009-0007-2935-926X)
- Wenjuan Zhang (ORCID: https://orcid.org/0000-0001-6972-6449)
- Nicole R Sarkaria
Institutions
- University of Minnesota (US)
- Mayo Clinic (US)
- Boehringer Ingelheim (Austria) (AT)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1093/noajnl/vdaf259
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute